Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Dec 21;26(6):588-597.
doi: 10.1097/GME.0000000000001282.

Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results

Sybil L Crawford  1 , Carolyn J Crandall  2 , Carol A Derby  3 , Samar R El Khoudary  4 , L Elaine Waetjen  5 , Mary Fischer  1 , Hadine Joffe  6   7
Affiliations
Multicenter Study

Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results

Sybil L Crawford et al. Menopause. .

Abstract

Objective: To better understand how to educate patients and providers about study findings relevant to treatment guidelines, we assessed pre- versus post-Women's Health Initiative (WHI) differences in menopausal hormone therapy (MHT) initiation and continuation and their correlates, and in women's reasons for initiation and discontinuation.

Methods: We analyzed survey data from up to 14 approximately annual visits over 17 years (1996-2013) from 3,018 participants in the Study of Women's Health Across the Nation, a prospective cohort study. We used logistic regression to compare pre- versus post-WHI associations of covariates with MHT initiation and continuation, and to compare pre- versus post-WHI reasons for initiation and continuation.

Results: MHT initiation dropped from 8.6% pre-WHI to 2.8% post-WHI (P < 0.0001), and the corresponding decrease in MHT continuation was 84.0% to 62.0% (P < 0.0001). Decreases in MHT initiation and continuation occurred across a range of participant subgroups, consistent with wide dissemination of post-WHI recommendations. However, contrary to current guidelines, we found large declines in MHT use in subgroups for whom MHT is often recommended, that is, younger women and those with more vasomotor symptoms. Post-WHI, women's reasons for MHT initiation and discontinuation reflected concerns highlighted by WHI results. The largest declines in initiation reasons were for reducing risks of osteoporosis and heart disease, whereas the largest increases in discontinuation reasons were for media reports and provider advice.

Conclusions: Immediate post-WHI recommendations for MHT use were widely adopted. MHT risks documented in older women, however, may have led younger symptomatic women to forgo MHT for symptom relief.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: No other potential conflicts of interest.

Figures

Figure 1a:
Figure 1a:
Menopausal hormone therapy initiation before and after Women’s Health Initiative July 2002 announcement by sociodemographic characteristics p-values for interaction between pre-WHI versus post-WHI and characteristic indicated by *p<0.05, **p<0.01, ***p<0.001
Figure 1b:
Figure 1b:
Menopausal hormone therapy initiation before and after Women’s Health Initiative July 2002 announcement by prior vasomotor symptom frequency and MHT use p-value for interaction between pre-WHI versus post-WHI and characteristic indicated by **p<0.01
Figure 1c:
Figure 1c:
Menopausal hormone therapy initiation before and after Women’s Health Initiative July 2002 announcement by menopausal stage
Figure 2a:
Figure 2a:
Menopausal hormone therapy continuation before and after Women’s Health Initiative July 2002 announcement by sociodemographic characteristics
Figure 2b:
Figure 2b:
Menopausal hormone therapy continuation before and after Women’s Health Initiative July 2002 announcement by prior vasomotor symptom frequency and MHT use p-values for interaction between pre-WHI versus post-WHI and characteristic indicated by *p<0.05, **p<0.01
Figure 2c:
Figure 2c:
Menopausal hormone therapy continuation before and after Women’s Health Initiative July 2002 announcement by menopausal stage
Figure 3a:
Figure 3a:
Reasons for menopausal hormone therapy initiation before and after Women’s Health Initiative July 2002 announcement p-values for pre-WHI versus post-WHI difference indicated by *p<0.05, **p<0.01, ***p<0.001
Figure 3b:
Figure 3b:
Reasons for menopausal hormone therapy discontinuation before and after Women’s Health Initiative July 2002 announcement p-values for pre-WHI versus post-WHI difference indicated by *p<0.05, **p<0.01, ***p<0.001
See this image and copyright information in PMC

Comment in

References

    1. Ettinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause 2012;19:610–615. - PubMed
    1. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women’s Health Initiative. Menopause 2012;19:616–621. - PubMed
    1. Weissfeld JL, Liu W, Woods C, et al. Trends in oral and vaginally administered estrogen use among US women 50 years of age and older with commercial health insurance. Menopause 2018;25:611–614. - PubMed
    1. North American Menopause Society. The 2017 position statement of the North American Menopause Society. Menopause 2017;24;728–753. - PubMed
    1. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015;100:3975–4011. - PubMed

Publication types